ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 156

Assessing the Role of Ascvd Score in Primary Thrombosis Prophylaxis Strategy Among Asymptomatic Antiphospholipid Antibody Carriers

Yu Zuo1, Akrithi Udupa2, Jennifer Fan1, Una E. Makris1, David Karp1,3 and Yu-min Shen1, 1University of Texas Southwestern Medical Center, Dallas, TX, 2Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 3Internal Medicine/Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Antiphospholipid antibodies, antiphospholipid syndrome, high risk, prevention and thrombosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Antiphospholipid Syndrome Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Primary thrombosis prophylaxis among asymptomatic antiphospholipid antibody (aPL) carriers is challenging. The presence of aPL does not always lead to thromboembolic events. Additional factors are needed to potentiate thrombus formation. A risk stratification tool to guide primary thrombosis prophylaxis among aPL positive carriers does not yet exist. Our study aims to evaluate the role of ASCVD score in primary thrombosis prophylaxis among asymptomatic aPL carriers.

Methods: This study included a convenience cohort of 198 persistent aPL positive patients who attended clinic at University of Texas Southwestern Medical Center. All patients had persistent high titer (≥99 percentiles) aPL. LA was tested by dilute Russell’s viper venom time, partial thromboplastin time–LA and silica clotting time, with appropriate cut-offs established in the laboratory. ASCVD is calculated based on patients’ age, total cholesterol, HDL, most recently documented systolic blood pressure, diabetes status, and smoking status. Pearson Chi-squared analysis was used to determine the association between increased ASCVD>10 and various thromboembolic events. Non-parametric comparison of ASCVD as a continuous variable was performed among different groups.

Results: Of the 198 aPL positive patients, 38 (19.2%) patients had arterial thrombosis, 72 (36.3%) had venous thrombosis, 7 had both arterial and venous thrombosis, and 95 (48.0%) were asymptomatic. Significantly higher 10-year CVD risk was seen among aPL patients with arterial thrombosis compared to asymptomatic carriers (P<0.0001). When comparing thrombotic APS patients to asymptomatic aPL positive carriers, 10-year CVD risk >7.5% (OR= 2.202, 95% CI 1.043–4.556, P=0.042) and 10-year CVD risk >10% (OR= 2.321, 95% CI 1.089-5.153, P=0.029) were significantly associated with arterial thrombosis but not venous thrombosis or any thrombosis. There were no significant CVD risk differences observed between aPL patients with venous thrombosis/or any thrombosis and asymptomatic carriers.

Conclusion: Increased 10 year cardiovascular disease risk determined by ASCVD among aPL positive patients is significantly associated with arterial thrombosis but not venous thrombosis. Since the protective effect of aspirin against incident thrombosis in all aPL carriers is not supported by randomized controlled data, our result suggests that ASCVD may be useful in identifying a subgroup of aPL carriers who benefit from aspirin.


Disclosure: Y. Zuo, None; A. Udupa, None; J. Fan, None; U. E. Makris, None; D. Karp, None; Y. M. Shen, None.

To cite this abstract in AMA style:

Zuo Y, Udupa A, Fan J, Makris UE, Karp D, Shen YM. Assessing the Role of Ascvd Score in Primary Thrombosis Prophylaxis Strategy Among Asymptomatic Antiphospholipid Antibody Carriers [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/assessing-the-role-of-ascvd-score-in-primary-thrombosis-prophylaxis-strategy-among-asymptomatic-antiphospholipid-antibody-carriers/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessing-the-role-of-ascvd-score-in-primary-thrombosis-prophylaxis-strategy-among-asymptomatic-antiphospholipid-antibody-carriers/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology